Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.

Medicine (Baltimore) · 2017 · PMC5515737 · PMID 28700465

Europe PMC DOI

hedged sentence

0.2290

closest p · 4.6× alpha

0.2290

boldest claim

The sentences

did not reach statistical significanceP = .229not close (p > 0.1)

The summary RRs indicate the risk of BPAR was reduced by 23% in patients receiving ALEM; however, this result did not reach statistical significance (RR: 0.77; 95% CI: 0.51–1.18; P = .229; Fig. 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.